XWAR
MAB
Market cap32mUSD
Oct 09, Last price
8.00PLN
1D
3.09%
1Q
8.40%
Jan 2017
-89.22%
IPO
-40.52%
Name
Mabion SA
Chart & performance
P/E
—
P/S
8.21
EPS
—
Div yield, %
—
Shrs. gr., 5y
3.33%
Rev. gr., 5y
%
Revenues
16m
-77.17%
Net income
-63m
L+888.54%
CFO
-42m
L
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Mabion S.A. is a Polish biopharmaceutical firm dedicated to pioneering the development of biological drugs, primarily leveraging monoclonal antibody technology. The company oversees the full spectrum from research and development to the manufacturing and commercialization of therapies designed to combat a wide range of diseases, including neoplastic (cancer), autoimmune, metabolic, and neurological disorders. Key products in its portfolio include MabionCD20 and MabionHER2. Established in 2007, Mabion S.A. maintains its headquarters in Konstantynów Lódzki, Poland.
Key people
Chairman of the Supervisory Board · since 2020
Chairman of the Supervisory Board · since 2018
Jolanta Baranowska
Chief Accounting Officer
Member of the Management Board · since 2019
Slawomir Jaros
Member of the Management Board · since 2011
Dirk Kreder
President of the Management Board · since 2020
Jaroslaw Kazimierz Walczak
Member of the Management Board
Jozef Banach
Independent Vice Chairman of the Supervisory Board
David John James
Independent Member of the Supervisory Board · since 2017
Jacek Piotr Nowak
Member of the Supervisory Board · since 2012
Tadeusz Pietrucha
Independent Member of the Supervisory Board · since 2011
Headquarters & legal address
Konstantynów Łódzki GEN. MARIANA LANGIEWICZA 60
Konstantynów Łódzki, 10 95-050
PL
Konstantynów Łódzki, 10 95-050
PL
Valuation
Title PLN in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||